Conference Track

From Podium to Practice: Updates in HBV Treatment

Source: CCO Official Conference Coverage of the 2010 Annual Meeting of the American Association for the Study of Liver Diseases

Capsule Summaries

Extending PegIFN alfa-2b From 24 to 48 Weeks Improves Responses in HBeAg-Positive Patients With Chronic Hepatitis B
Extending PegIFN alfa-2a From 48 to 96 Weeks Well Tolerated With Similar Incidence of Adverse Events in HBeAg-Negative Patients With Genotype D HBV
Alcohol Abuse and Diabetes Contribute to Severe Liver Disease Outcomes in Patients With Chronic Hepatitis B
Telbivudine Use in Late Pregnancy in HBeAg-Positive Mothers Safely Reduces Perinatal HBV Transmission
PegIFN 180 µg/week for 48 Weeks Provides Highest Seroconversion Rate vs Lower Dose and/or Shorter Treatment Duration in HBeAg-Positive HBV Infection
Elective Cesarean Section Lowers Risk of Perinatal HBV Transmission in Newborns Undergoing Standard Immunoprophylaxis
Tenofovir Provides Effective and Sustained Virologic Suppression in HBeAg-Positive HBV-Infected Patients Through 192 Weeks

Expert Analysis

From Podium to Practice: Updates in HBV Treatment

Faculty:

Anna S. F. Lok, MD
Patrick Marcellin, MD
Norah Terrault, MD, MPH

Learning Objectives

Upon completion of this activity, participants should be able to:

Recount new data from clinical studies evaluating the safety and efficacy of long-term tenofovir therapy in patients with chronic hepatitis B
Apply the results of recent studies investigating the impact of dose and treatment duration on the safety and efficacy of peginterferon therapy for the treatment of chronic hepatitis B
Evaluate the latest findings from studies examining the impact of mode of delivery and antiviral therapy during late pregnancy on perinatal HBV transmission risk
Devise patient management strategies that reflect recent data on the incidence and correlates of hepatocellular carcinoma, decompensated cirrhosis, and liver-related death among patients with chronic HBV infection treated in a community setting

CREDIT INFORMATION

Release Date: 12/17/10

Expiration Date: 12/16/11

Physicians: maximum of 1.0 AMA PRA Category 1 Credit™

Status: The activity is not currently available for credit.

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.